Preconditioned Human Mesenchymal Stem Cells (hMSCs) for Musculoskeletal Tissue Repair
Improved cell survival and engraftment Able to manipulate biophysical properties of spheroid-hydrogel system
Bone repair Orthopedic and plastic surgery Tissue repair
Bone defects that extend beyond a critical size are associated with impaired native healing due to age or disease. Approximately 10% of patients with bone defects do not have sufficient bone repair processes, leading to fractures, infections, and other comorbidities. Human mesenchymal stem cell (hMSC)-based therapies have high therapeutic potential for such bone repair but have limited efficacy in vivo: calcification of surrounding tissue occurs due to limited oxygen supply and decreased nutrient exchange. Researchers at the University of California, Davis have developed a novel treatment for bone repair that offers an optimized survival rate of human mesenchymal stem cells and engraftment once implanted into a bone defect. The method incorporates pre-treatment of the cells combined with an engineered cell carrier system, resulting in synergistically improved bone healing compared to existing monolayer cell therapies and spheroid formation methods. This method has successfully exhibited higher cell density, osteogenic potential and increased secretion of proangiogenic factors in vitro with significantly more bone healing in critical-sized femoral segment defects in rats in vivo. This method represents a simple approach for enhanced, long-term therapeutic bone healing.
Tech ID/UC Case 29121/2018-293-0 Related Cases 2018-293-0
USA
